Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Aug 11, 2025 04:05PM
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences Aug 28, 2024 04:05PM
Ryan Reynolds Announces More to Parkinson’s® Campaign Aug 14, 2024 08:04AM
Acadia Pharmaceuticals to Participate in the Canaccord Genuity 44th Annual Growth Conference Aug 7, 2024 04:30PM
Acadia Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operating Overview Aug 6, 2024 04:05PM
View Older Stories

Jul 24, 2024 04:05PM Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2024
Jul 18, 2024 09:05AM Acadia Pharma (ACAD): Clinical Data from Open-Label Extension LILAC-1 and LILAC-2 Studies Evaluating DAYBUE in Patients with Rett Syndrome Published
Jul 18, 2024 09:04AM Clinical Data from Open-Label Extension LILAC-1™ and LILAC-2™ Studies Evaluating Long-Term Safety and Efficacy of DAYBUE™ (trofinetide) in Patients with Rett Syndrome Published in Med
Jun 18, 2024 09:04AM Acadia Pharma (ACAD) Presents DAYBUE Real-World Evidence and Additional Data in Rett Syndrome
Jun 18, 2024 09:04AM Acadia Pharmaceuticals Presents DAYBUE™ (trofinetide) Real-World Evidence and Additional Data in Rett Syndrome at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting
May 17, 2024 04:05PM Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 15, 2024 09:05AM Acadia Pharmaceuticals Announces Launch of Magnolia's Guide to Adventuring: A Groundbreaking Documentary Series Aiming to Raise Disease Awareness and Redefine Perceptions of Rett Syndrome
May 9, 2024 04:58PM Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
May 8, 2024 04:05PM Acadia Pharmaceuticals Reports First Quarter 2024 Financial Results and Operating Overview
Apr 29, 2024 04:16PM Acadia Pharmaceuticals is Proud to Announce the Winners of the Inaugural Rett Sibling Scholarship
Apr 24, 2024 04:05PM Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024
Apr 22, 2024 09:04AM Acadia Pharma (ACAD) Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada
Apr 22, 2024 09:04AM Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada
Apr 19, 2024 04:05PM Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apr 17, 2024 04:05PM Acadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting
Apr 2, 2024 04:06PM Acadia Pharma (ACAD) Appoints Elizabeth H. Z. Thompson as Head of R&D
Apr 2, 2024 04:05PM Acadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development
Apr 1, 2024 04:05PM Acadia Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Mar 15, 2024 04:05PM Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 13, 2024 04:05PM Acadia Pharmaceuticals to Participate in the UBS Virtual CNS Day
Mar 11, 2024 04:05PM Acadia Pharma (ACAD) Reports Top-Line Results from Phase 3 ADVANCE-2 Trial of Pimavanserin
Mar 11, 2024 04:05PM Acadia Pharmaceuticals Announces Top-Line Results from Phase 3 ADVANCE-2 Trial of Pimavanserin in Negative Symptoms of Schizophrenia
Feb 29, 2024 09:05AM Acadia Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference on March 6, 2024
Feb 27, 2024 04:05PM Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operating Overview
Feb 21, 2024 04:05PM Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb 13, 2024 04:05PM Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
Jan 31, 2024 04:29AM Acadia Pharma (ACAD) Appoints Jennifer J. Rhodes as Chief Legal Officer and Secretary, Kimberly J. Manhard as SVP, Global Strategic Planning and Execution
Jan 30, 2024 08:48PM Acadia Announces Additions to Executive Team
Jan 19, 2024 04:05PM Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan 18, 2024 04:05PM Acadia Pharma (ACAD) Announces the Passing of Former President Srdjan (Serge) Stankovic
Jan 18, 2024 04:05PM Acadia Announces the Passing of Former President Srdjan (Serge) Stankovic
Dec 21, 2023 04:05PM Acadia Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024
Dec 18, 2023 04:05PM Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dec 14, 2023 03:49AM Acadia Pharma (ACAD) Reports Delaware District Court Rules in Favor of Acadia on Formulation Patent Construction Claims Regarding NUPLAZID
Dec 13, 2023 09:24PM Delaware District Court Rules in Favor of Acadia on Formulation Patent Construction (Markman) Claims Regarding NUPLAZID® (pimavanserin)
Dec 13, 2023 01:42PM Acadia Pharma (ACAD) Reports Delaware Federal District Court Ruled in Favor of Acadia in NUPLAZID Patent Litigation
Dec 13, 2023 01:41PM Delaware Federal District Court Rules in Favor of Acadia Pharmaceuticals in NUPLAZID® (pimavanserin) Patent Litigation
Nov 30, 2023 09:05AM Acadia Pharmaceuticals Initiates Pivotal Phase 3 Study of Carbetocin (ACP-101) for the Treatment of Hyperphagia in Prader-Willi Syndrome
Nov 27, 2023 09:06AM Acadia Pharma (ACAD) Initiates Phase 2 Clinical Trial of ACP-204
Nov 27, 2023 09:05AM Acadia Pharmaceuticals Initiates Phase 2 Clinical Trial of ACP-204 for the Treatment of Alzheimer’s Disease Psychosis
Nov 21, 2023 05:00PM Acadia Pharma (ACAD) Announces Departure of Doug Williamson, EVP and Head of Research and Development
Nov 21, 2023 05:00PM Acadia Pharmaceuticals Announces Change in Research and Development Leadership
Nov 14, 2023 04:12PM Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 2, 2023 04:05PM Acadia Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operating Overview
Oct 31, 2023 04:05PM Acadia Pharmaceuticals to Participate in the Guggenheim Securities 5th Annual Inflammation & Immunology Conference
Oct 23, 2023 09:05AM Acadia Pharmaceuticals Announces the Rett Sibling Scholarship Program
Oct 19, 2023 04:05PM Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 2, 2023
Oct 18, 2023 05:00PM Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 22, 2023 06:23PM Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 19, 2023 04:05PM Acadia Pharmaceuticals Appoints Albert Kildani as Senior Vice President, Investor Relations and Corporate Communications
View Older Stories